Orphan Drug Prices To Face Fiscal Cliff Scrutiny, NORD Expects
This article was originally published in The Pink Sheet Daily
If the debate does include a focus on entitlement spending, NORD does not plan on taking sides.
You may also be interested in...
In the first half of 2013, two drugs for serious, ultra-rare diseases will have launched in the U.S. priced at $250,000 annually. One is encountering minimal resistance among payers; the other is expected to face a hard road. Plus a look at Celgene/Forma, Bayer/Conceptus, Soligenix/Intrexon; Regeneron/Sanofi and more.
As personalized medicine continues to grow, FDA is watching to see if there is a rise in orphan designations for products targeting a “smaller slice” of a common disease.
Label expansion efforts for Vertex’s cystic fibrosis therapy will be claims taken through FDA’s new review pathway; the initial product could reach more patients more quickly and serve as a guide to how the agency will handle drugs earmarked for streamlined development and approval.